Integrated Dose Counter Supply Agreement

News Release

4 February 2015

Consort Medical plc signs multi-year supply agreement for its proprietary integrated dose counter (IDC) system

First agreement for oral variant of IDC-containing device

Significant commercial opportunity underscores strength of respiratory franchise

Hemel Hempstead, UK, 4 February 2015 - Consort Medical plc (LSE: CSRT) ("Consort", "Consort Medical" or the "Group"), a leading, global single source drug and delivery company, today announces the conclusion of a significant new commercial supply agreement for its proprietary integrated dose counter (IDC) system. The multi-year supply agreement covers supply of both the IDC actuator and the pressurised metered dose inhaler (pMDI) valve. This IDC programme represents the first commercial oral variant of the device, which is already approved and marketed for a nasally delivered product.

Dose-counting devices fulfil an important patient and compliance need to let patients know if their device contains sufficient drug and to indicate when they need to seek a further prescription. It provides patients with a reliable, easy to read indication of how many doses are left inside the canister in line with FDA guidance.

Jonathan Glenn, Consort Medical's Chief Executive Officer commented:"Consort Medical has a long heritage of excellence, reliability and innovation and we strive to be the partner of choice for pharmaceutical companies, enabling them to implement drug delivery technologies that can streamline and accelerate the route to market for their drugs.

"With the conclusion of this agreement for our IDC device we have reinforced the ongoing strength of our respiratory device franchise, in particular in the pMDI segment, and created a significant business opportunity."

The device will be manufactured in the Consort Medical company Bespak's existing IDC facility at King's Lynn. The project will be referred to as (IDC300).

-Ends-

Enquiries:

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Our businesses

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). To learn more about our company visit our website at www.consortmedical.com.